Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BioNTech Revenues Slide with Waning Demand for COVID-19 Vaccines | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

BioNTech Revenues Slide with Waning Demand for COVID-19 Vaccines

Approximately 2 billion doses of COMIRNATY invoiced in 2022, including approximately 550 million doses of Omicron-adapted bivalent COVID-19 vaccines.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BioNTech
4Q Revenues: €4.3 billion (-23%)
4Q Earnings: €2.3 billion (-28%)
YTD Revenues: €17.3 billion (-9%)
YTD Earnings: €9.3 billion (-8%)
Comments: Results in the quarter and FY reflect lower demand for COVID-19 vaccines. Approximately 2 billion doses of COMIRNATY invoiced in 2022, including approximately 550 million doses of Omicron-adapted bivalent COVID-19 vaccines.
 
BioNTech expanded its oncology pipeline to 20 programs with 24 ongoing clinical trials including five Phase 2 clinical trials.
 
R&D expenses were €509.8 million in the quarter, compared to €271.5 million for the comparative prior year period. For the year R&D expenses were €1.5 billion, compared to €949.2 million for the comparative prior year period. 
 
In November 2022, BioNTech and Pfizer initiated a Phase 1 clinical trial to evaluate the safety, tolerability, and immunogenicity of BNT162b4, a next-generation COVID-19 vaccine candidate that aims to enhance SARS-CoV-2 T cell responses and potentially broaden protection against upcoming variants and increase durability of protection.
 
In October 2022, BioNTech and Pfizer initiated a Phase 1 open-label, dose-finding clinical trial to evaluate the safety, tolerability, and immunogenicity of a combination of the COVID-19 and influenza mRNA vaccines and COVID-19 with a single injection. In December, BioNTech and Pfizer received Fast Track Designation from the U.S. FDA for the combination vaccine candidate.
 
The company is also working on the following vaccines: herpes simplex virus vaccine HSV-2 Vaccine Program – BNT163, Malaria Vaccine Program – BNT165, and a Shingles Vaccine Program – BNT167 with Pfizer.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters